# Scott Greenberg

> Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.

- **Role:** Chief Business Officer at Nura Bio
- **Organizations:** Nura Bio, Aro Biotherapeutics, Roivant Sciences, Celgene Corporation, Goldman Sachs & Co.
- **Nationality:** American
- **Education:** BS, Finance and Biological Basis of Behavior, University of Pennsylvania, MBA, Harvard Business School
- **Known for:** More than 20 years of leadership across business development, R&D strategy and operations in biopharma, Led fundraising, finance and corporate strategy as COO of Aro Biotherapeutics, Helped scale and operate Roivant Sciences as VP, Head of Operations

## Career timeline

- **Early career** — Began in investment banking at Goldman Sachs & Co.
- **2000s-2010s** — Spent more than a decade at Celgene Corporation (acquired by Bristol-Myers Squibb) across business development, R&D strategy, R&D project leadership, sales and marketing
- **Later** — Vice President, Head of Operations at Roivant Sciences
- **Recent** — Chief Operating Officer at Aro Biotherapeutics, leading fundraising, finance, business development, corporate strategy, new product planning and project management
- **2025-02** — Appointed Chief Business Officer of Nura Bio

## Achievements

- More than 20 years of leadership across business development, R&D strategy and operations in biopharma
- Led fundraising, finance and corporate strategy as COO of Aro Biotherapeutics
- Helped scale and operate Roivant Sciences as VP, Head of Operations
- Over a decade of cross-functional leadership at Celgene through its growth into a major oncology company
- Dual undergraduate degrees from Penn plus a Harvard MBA

## Latest updates

- **2025-02** — Named Chief Business Officer of Nura Bio as the company expanded its C-suite for its next phase of clinical development.

## Links

- Website: https://nurabio.com
- LinkedIn: http://www.linkedin.com/in/scott-greenberg-6397a23

---

Profile page: https://yespress.io/scott-greenberg
Published by YesPress — https://yespress.io
Last updated: 2026-06-20